Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) being major risk factors. Despite advances in numerous therapy modalities, survival rates for HNSCC have not improved considerably...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-07-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523322000857 |
| _version_ | 1818208586844602368 |
|---|---|
| author | Bharat Goel Anoop Kumar Tiwari Rajeev Kumar Pandey Akhand Pratap Singh Sujeet Kumar Abhishek Sinha Shreyans K. Jain Arun Khattri |
| author_facet | Bharat Goel Anoop Kumar Tiwari Rajeev Kumar Pandey Akhand Pratap Singh Sujeet Kumar Abhishek Sinha Shreyans K. Jain Arun Khattri |
| author_sort | Bharat Goel |
| collection | DOAJ |
| description | Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) being major risk factors. Despite advances in numerous therapy modalities, survival rates for HNSCC have not improved considerably; a vast number of clinical outcomes have demonstrated that a combination strategy (the most well-known docetaxel, cisplatin, and 5-fluorouracil) is the most effective treatment choice. Immunotherapy that targets immunological checkpoints is being tested in a number of clinical trials, either alone or in conjunction with chemotherapeutic or targeted therapeutic drugs. Various monoclonal antibodies, such as cetuximab and bevacizumab, which target the EGFR and VEGFR, respectively, as well as other signaling pathway inhibitors, such as temsirolimus and rapamycin, are also being studied for the treatment of HNSCC. We have reviewed the primary targets in active clinical studies in this study, with a particular focus on the medications and drug targets used. |
| first_indexed | 2024-12-12T04:47:11Z |
| format | Article |
| id | doaj.art-fd8fd0f682164e99b08cb2190c5db831 |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-12-12T04:47:11Z |
| publishDate | 2022-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-fd8fd0f682164e99b08cb2190c5db8312022-12-22T00:37:35ZengElsevierTranslational Oncology1936-52332022-07-0121101426Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trialsBharat Goel0Anoop Kumar Tiwari1Rajeev Kumar Pandey2Akhand Pratap Singh3Sujeet Kumar4Abhishek Sinha5Shreyans K. Jain6Arun Khattri7Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi - 221005, Uttar Pradesh, IndiaDepartment of Pharmaceutical Engineering and Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi - 221005, Uttar Pradesh, IndiaDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, United StatesDepartment of Pharmaceutical Engineering and Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi - 221005, Uttar Pradesh, IndiaCentre for Proteomics and Drug Discovery, Amity Institute of Biotechnology, Amity University Maharashtra, Mumbai - 410206, Maharashtra, IndiaDepartment of Oral Medicine & Radiology, Sardar Patel Post Graduate Institute of Dental & Medical Sciences, Lucknow - 226025, Uttar Pradesh, IndiaDepartment of Pharmaceutical Engineering and Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi - 221005, Uttar Pradesh, IndiaDepartment of Pharmaceutical Engineering and Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi - 221005, Uttar Pradesh, India; Corresponding author: Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi 221005, Uttar Pradesh, India.Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) being major risk factors. Despite advances in numerous therapy modalities, survival rates for HNSCC have not improved considerably; a vast number of clinical outcomes have demonstrated that a combination strategy (the most well-known docetaxel, cisplatin, and 5-fluorouracil) is the most effective treatment choice. Immunotherapy that targets immunological checkpoints is being tested in a number of clinical trials, either alone or in conjunction with chemotherapeutic or targeted therapeutic drugs. Various monoclonal antibodies, such as cetuximab and bevacizumab, which target the EGFR and VEGFR, respectively, as well as other signaling pathway inhibitors, such as temsirolimus and rapamycin, are also being studied for the treatment of HNSCC. We have reviewed the primary targets in active clinical studies in this study, with a particular focus on the medications and drug targets used.http://www.sciencedirect.com/science/article/pii/S1936523322000857HNSCCImmunotherapyClinical trialPD-1EGFRImmune checkpoints |
| spellingShingle | Bharat Goel Anoop Kumar Tiwari Rajeev Kumar Pandey Akhand Pratap Singh Sujeet Kumar Abhishek Sinha Shreyans K. Jain Arun Khattri Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials Translational Oncology HNSCC Immunotherapy Clinical trial PD-1 EGFR Immune checkpoints |
| title | Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials |
| title_full | Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials |
| title_fullStr | Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials |
| title_full_unstemmed | Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials |
| title_short | Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials |
| title_sort | therapeutic approaches for the treatment of head and neck squamous cell carcinoma an update on clinical trials |
| topic | HNSCC Immunotherapy Clinical trial PD-1 EGFR Immune checkpoints |
| url | http://www.sciencedirect.com/science/article/pii/S1936523322000857 |
| work_keys_str_mv | AT bharatgoel therapeuticapproachesforthetreatmentofheadandnecksquamouscellcarcinomaanupdateonclinicaltrials AT anoopkumartiwari therapeuticapproachesforthetreatmentofheadandnecksquamouscellcarcinomaanupdateonclinicaltrials AT rajeevkumarpandey therapeuticapproachesforthetreatmentofheadandnecksquamouscellcarcinomaanupdateonclinicaltrials AT akhandpratapsingh therapeuticapproachesforthetreatmentofheadandnecksquamouscellcarcinomaanupdateonclinicaltrials AT sujeetkumar therapeuticapproachesforthetreatmentofheadandnecksquamouscellcarcinomaanupdateonclinicaltrials AT abhisheksinha therapeuticapproachesforthetreatmentofheadandnecksquamouscellcarcinomaanupdateonclinicaltrials AT shreyanskjain therapeuticapproachesforthetreatmentofheadandnecksquamouscellcarcinomaanupdateonclinicaltrials AT arunkhattri therapeuticapproachesforthetreatmentofheadandnecksquamouscellcarcinomaanupdateonclinicaltrials |